Stock vs Stock Comparison

Amgen Inc. vs AbbVie Inc.

AMGN wins the Tale of the Tape 5–3.

AMGN$328.26
ABBV$215.40

🏆 Tale of the Tape

53
AMGNABBV
21.0%Profitability (Net Margin)6.9%
23.4xValuation (P/E)106.2x
14.2%Efficiency (ROIC)8.3%
7/9Health (Piotroski F)7/9
1.9Safety (Altman Z)2.0
10.0%Growth (Rev YoY)8.6%
0.73Risk (Sharpe 1Y)0.61
9.46xBalance Sheet (D/E)-42.50x
3.52%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.526
252-Day Correlation
0.380
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricAMGNABBV
Market Cap$181.8B$384.7B
P/E Ratio23.4x106.2x
Forward P/E14.3x13.4x
P/B19.78x-57.80x
Dividend Yield2.99%3.18%
Beta0.430.30

Quantitative Metrics

MetricAMGNABBV
DCF Fair Value$264.36$126.26
DCF Upside-24.4%-38.9%
Piotroski F7/97/9
Altman Z1.882.01
Beneish M-2.26-2.87
FCF Yield3.52%4.23%
Net Debt/EBITDA2.4x3.0x
ROIC14.2%8.3%
WACC7.1%7.4%
ROIC – WACC7.1pp0.8pp
Gross Margin67.3%70.2%
Net Margin21.0%6.9%
Rev Growth YoY10.0%8.6%
Sharpe (1Y)0.730.61
Max Drawdown 3Y
FCF Payout Ratio63%65%

AMGN Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

AMGN found in:

IBB7.46%
DIA4.13%
SCHD3.93%
IYH3.41%
XLV3.39%
VHT3.02%
MOAT1.45%
XBI1.03%
QQQ0.97%
MGV0.93%
VIG0.84%
VTV0.73%
VYM0.71%
SCHV0.70%
IWF0.50%
VONG0.44%
ESGV0.38%
SPYG0.35%
SCHX0.34%
SCHB0.31%
IVV0.30%
VOO0.30%
SPY0.28%
VONE0.28%
VTI0.27%
SPLG0.27%
ITOT0.27%
SPTM0.26%
VFVA0.25%
URTH0.24%
RSP0.21%
SPYV0.20%
ACWI0.19%
VFMO0.18%
QUS0.17%
IWD0.16%
VT0.16%
VONV0.15%
ONEO0.09%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

AMGN vs ABBV: Head-to-Head Analysis

Amgen Inc. (AMGN) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, AMGN leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, AMGN generates a return on invested capital (ROIC) of 14.2% compared to ABBV's 8.3%. This suggests AMGN is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between AMGN and ABBV is 0.526, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

AMGN appears in 39 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, AMGN or ABBV?

Our quantitative analysis compares AMGN and ABBV across nine fundamental dimensions. AMGN wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are AMGN and ABBV correlated?

The 252-day correlation between AMGN and ABBV is 0.526. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.